Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Capital Expenditures (2016 - 2025)

ImmunityBio (IBRX) has disclosed Capital Expenditures for 12 consecutive years, with $792000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 5.88% to $792000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2025, up 81.15% year-over-year, with the annual reading at $1.4 million for FY2025, 81.15% up from the prior year.
  • Capital Expenditures for Q4 2025 was $792000.0 at ImmunityBio, up from -$741000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $28.0 million in Q4 2021, with the low at -$9.5 million in Q3 2021.
  • Average Capital Expenditures over 5 years is $7.2 million, with a median of $3.6 million recorded in 2023.
  • Peak annual rise in Capital Expenditures hit 18809.3% in 2021, while the deepest fall reached 4873.0% in 2021.
  • Over 5 years, Capital Expenditures stood at $28.0 million in 2021, then plummeted by 32.34% to $18.9 million in 2022, then crashed by 57.98% to $8.0 million in 2023, then tumbled by 90.6% to $748000.0 in 2024, then rose by 5.88% to $792000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $792000.0, -$741000.0, and $197000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.